CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 109 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q1 2022. The put-call ratio across all filers is 0.45 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,825,840 | -64.3% | 83,639 | -48.0% | 0.00% | -100.0% |
| Q2 2023 | $5,108,652 | -5.1% | 160,700 | -27.2% | 0.00% | 0.0% |
| Q1 2023 | $5,384,433 | -69.0% | 220,764 | -60.0% | 0.00% | -50.0% |
| Q4 2022 | $17,393,585 | +22.9% | 551,477 | +10.1% | 0.00% | 0.0% |
| Q3 2022 | $14,157,000 | +39.0% | 500,957 | +30.0% | 0.00% | +100.0% |
| Q2 2022 | $10,186,000 | +175.5% | 385,284 | +264.8% | 0.00% | – |
| Q1 2022 | $3,697,000 | +165.8% | 105,610 | +146.1% | 0.00% | – |
| Q4 2021 | $1,391,000 | +81.1% | 42,915 | +64.6% | 0.00% | – |
| Q3 2021 | $768,000 | +93.5% | 26,078 | +68.0% | 0.00% | – |
| Q2 2021 | $397,000 | +443.8% | 15,527 | +193.0% | 0.00% | – |
| Q1 2021 | $73,000 | -69.3% | 5,300 | -63.2% | 0.00% | – |
| Q4 2020 | $238,000 | – | 14,386 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 60,632,356 | $1,965,701,000 | 23.51% |
| Affinity Asset Advisors, LLC | 225,000 | $7,295,000 | 2.65% |
| Perceptive Advisors | 10,173,454 | $329,822,000 | 2.54% |
| Artal Group S.A. | 1,500,000 | $48,630,000 | 1.32% |
| Rock Springs Capital Management LP | 1,648,435 | $53,442,000 | 1.24% |
| RTW INVESTMENTS, LP | 666,666 | $21,613,000 | 0.32% |
| BOULDER HILL CAPITAL MANAGEMENT LP | 8,900 | $289,000 | 0.28% |
| EAM Investors, LLC | 39,907 | $1,294,000 | 0.21% |
| FEDERATED HERMES, INC. | 3,113,333 | $100,934,000 | 0.19% |
| Alkeon Capital Management | 1,909,035 | $61,891,000 | 0.12% |